Member Info for Energyshares

Vote him out, No wonder we are in this mess.

Another way to move to a quicker FDA approval.

I wonder if Avacta have signed up.

AVA6000 meets all the criteria:

Purpose of the RTOR

The Oncology Center of Excellence Real-Time Oncology Review (RTOR) aims to provide a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while improving review quality and engaging in early iterative communication with the applicant. 

RTOR facilitates earlier submission of topline efficacy and safety results, prior to the submission of the complete application, to support an earlier start to the FDA’s evaluation of the application.

Submissions to be considered for the RTOR program should meet the following criteria:

* Drugs likely to demonstrate substantial improvements over available therapy or meeting criteria for Expedited Programs.

* Straightforward study designs.

* Endpoints that can be easily interpreted (e.g., overall survival, response rates, etc.).

FDA will also consider whether adequate dose optimization has been performed to support the proposed dosage. Submissions with greater complexity will be considered for RTOR on a case by case basis. Additionally, FDA prefers the Assessment Aid (AAid)be used with RTOR.

https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review

Avacta with has a £160m MCap now,

BOD halved the value of the company to receive just £31m.

Doesn’t want to do small deals to protect IP in case they receive BP deal.

Has done multiple deals in the past for just a few million upfront payments.

Doesn’t make any sense….

Can’t wait for Monday with the 40 day blackout lifted on Friday after trading.

18th March to 26th April.

Why the blackout ?

Fund has invested NASDAQ rules.

Could it be one of these funds who all invest in ground breaking science.

Let’s hope for an after hours RNS Friday….

Takeda Ventures Inc

https://www.takeda.com/science/research-and-development/partnerships/tdv/

Pfizer Ventures Inc

https://www.pfizer.com/about/partners/venture-investments

Novartis Venture Fund

https://www.nvfund.com/

GLA..

Can I order these for Gardiner.

https://www.bouncykings.co.uk/category/side-stall-and-garden-games/702/wooden-stocks

PL are yours better than these…

https://www.ebay.co.uk/b/bn_75394466

Over subscribed by II’s and oversubscribed by PI’s,Raising 31 million.

Why didn’t they just ask the market for £70 million explain its to pay off Heights and cash for trials.

Although more diluted but with heights gone and AACR data release,SP and Avacta would be in a very strong position now.

Avacta are a sitting duck for a low ball T/O offer thanks to this incompetence of board.

They turned down extra cash at 50p to then issue more stock at 42p.

If Gardiner resigns ASAP we could see a bounce in SP because the Market has no confidence in this CFO.

Gardiner under massive pressure now, can he last the week ?

The cheeky twat will probably give him & Smith more options.

You couldn’t make it up….

Gardiner hasn’t got a clue….

Needs to go ASAP

WET Cancer

Board cancer

“My take on what’s going on:”

That’s just my opinion we are all entitled to opinions you have enough

They need accounts signed off and No LD to fund hence car crash placing and dumping DX

The drug was approved 50+ years ago we are talking about a new delivery mechanism for an already approved drug that has nasty side effects.

Ava6000 eliminates these side effects and delivers more drug to the tumour and this is now proven.

My take on what’s going on:

Late last year Avacta was about to sign a LD with a major BP, hence the “dont worry about the funding “ comment.

But the results of the data coming in changed all this and the FDA are now in the driving seat with this trial knowing they want this to market ASAP.

For AS to state they have the Holy Grail after P1A data is the biggest hint to us all.

AS stated in Q&A we are in close talks with FDA and don’t want to jeopardise those talks on answering questions related to the trial.

P1B was suddenly changed to the 2W dose on FDA guidance.

( FDA don’t change your trial for more potent dosing then ask you to go back to original trial for P2)

Accelerated Approval is coming after 2W dose results.

That’s why LD was pulled and new terms are now being thrashed out for a BP partnership to get AVA6000 to market ASAP

It’s not the market that will light the fuse for Avacta’s SP rocket but the FDA

Call me a ramper if you want but just look at the evidence.

GLA

Reading blog below, I’m very very positive that AVA6000 receives FDA approval.

Just a Box ticking exercise for Avacta now.

https://www.science.org/content/blog-post/als-drug-fails-again

Tony joined Avacta from AHR, an international architecture and building consultancy practice, where he has held the role of Finance Director since 2011.

Not the experience you want doing billion pound deals…..

Winging it ….

Resign Gardiner you out of your depth and have cost thousands of LTH’s a massive drop in their net worth.

Everyone needs to hold to get back in the black, but we can’t let this man run the finance’s any longer with multi billion pound deals coming soon, use your votes at AGM to get rid.

Smith departed to the mountain bunker and stayed there for 40 days and nights in order to receive the 50p placing.

He was kept silent while the company has lost over half its value in that time because of the rules of his placement.

Pitch forks are out now and X (twitter) SH’s want him out.

I prefer Gardiner to go first with Smith moved sideways.

Yanks know about us….

Paula Takacs Foundation.

Since our inception in 2010, we have emerged one of the most active grassroots sarcoma foundations in the U.S.

https://paulatakacsfoundation.org/about-us/

https://paulatakacsfoundation.org/soft-tissue-sarcoma-pipeline-insight/

Little Avacta gets a mention.

* In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in the tumor with the aim of sparing healthy tissue from exposure and improving the safety, tolerability, and efficacy of the drug.

WET Cancer on here

jonathan his**** (born april 1974)[1] is a british hedge fund manager and founder of gsa capital, a london-based hedge fund.

shame on him shorting a company trying to save lives.

i wonder if the big c comes a knocking at his door or family members

Smith can’t be defended and needs to pull a bloody big rabbit out the bag to save his bacon.

Won’t do a deal with smaller companies so he gets a bigger deal later on.???

Just do a deal secure the cash and let BP decide what they are going to do about the smaller deals already done,If it’s the Holy Grail they will buy them out as well.

Just get LTH’s back in the black from the bloody car crash of a placing.

3 years of empty promises and kicking the can down the road.

LTH’ s need to see some action and answers from this board.